Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on May 14, 2007

Circulation. 2007
Published online before print May 14, 2007, doi: 10.1161/CIRCULATIONAHA.106.671420
A more recent version of this article appeared on May 29, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/21/2715    most recent
CIRCULATIONAHA.106.671420v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lavi, S.
Right arrow Articles by Lerman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lavi, S.
Right arrow Articles by Lerman, A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Coronary Artery Disease
Related Collections
Right arrow Coronary circulation
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Other Vascular biology
Right arrow Pathophysiology
Right arrow Doppler ultrasound, Transcranial Doppler etc.
Right arrowRelated Article

Submitted on October 19, 2006
Accepted on March 26, 2007

Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation. Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans

Shahar Lavi MD, Joseph P. McConnell PhD, Charanjit S. Rihal MD, Abhiram Prasad MD, Verghese Mathew MD, Lilach O. Lerman MD, PhD, and Amir Lerman MD*

From the Division of Cardiovascular Diseases (S.L., C.S.R., A.P., V.M., L.O.L., A.L.), Department of Laboratory Medicine and Pathology (J.P.M.), and Division of Nephrology and Hypertension (L.O.L.), Mayo Clinic, Rochester, Minn.

* To whom correspondence should be addressed. E-mail: Lerman.Amir{at}mayo.edu.

Background--Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel marker and participant in vascular inflammation. Inflammation also is associated with coronary atherosclerosis. We tested the hypothesis that local coronary production of Lp-PLA2 is enhanced in patients with early coronary atherosclerosis and associated with local endothelial function.

Methods and Results--Coronary angiography, blood flow, flow reserve, endothelial function assessment, and intravascular ultrasound with volumetric analysis were performed in 15 patients with mild coronary atherosclerosis and in 15 control subjects. Plasma samples were collected simultaneously from the left main coronary artery and coronary sinus for measurement of Lp-PLA2, lysophosphatidylcholine (a product of Lp-PLA2), and C-reactive protein. Hemodynamic parameters and cholesterol were similar in both groups. Arterial Lp-PLA2 levels were similar in patients and control subjects: 225 ng/mL (interquartile range [IQR], 196 to 273 ng/mL) versus 221 ng/mL (IQR, 177 to 294 ng/mL). Lp-PLA2 net production in the coronary circulation was higher in patients compared with control subjects: 519 ng/min (IQR, 198 to 1276 ng/min) versus -529 ng/min (IQR, -872 to -79 ng/min; P=0.001) and correlated with percent atheroma volume (rs=0.37, P=0.04). Net production of lysophosphatidylcholine was higher in patients compared with control subjects: 199 ng/min (IQR, -592 to 470 ng/min) versus -505 ng/min (IQR, -1119 to 0 ng/min; P=0.03) and correlated with coronary endothelial dysfunction (rs=0.5, P=0.005). C-reactive protein was not significantly different between the groups.

Conclusions--Early coronary atherosclerosis in humans is characterized by local production of Lp-PLA2. Local coronary production of lysophosphatidylcholine, the active product of Lp-PLA2, is associated with endothelial dysfunction. These results support the role for Lp-PLA2 in the mechanism of regional vascular inflammation and atherosclerosis in humans.


Key words: atherosclerosis • endothelium • inflammation • vasculature


Related Article:

Issue Highlights
Circulation 2007 115: 2683. [Full Text]



This article has been cited by other articles:


Home page
J. Lipid Res.Home page
A. Vinson, M. C. Mahaney, V. P. Diego, L. A. Cox, J. Rogers, J. L. VandeBerg, and D. L. Rainwater
Genotype-by-diet effects on co-variation in Lp-PLA2 activity and LDL-cholesterol concentration in baboons fed an atherogenic diet
J. Lipid Res., June 1, 2008; 49(6): 1295 - 1302.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. Koenig
Treating Residual Cardiovascular Risk: Will Lipoprotein-Associated Phospholipase A2 Inhibition Live Up to Its Promise?
J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1642 - 1644.
[Full Text] [PDF]


Home page
HypertensionHome page
S. Lavi, E. H. Yang, A. Prasad, V. Mathew, G. W. Barsness, C. S. Rihal, L. O. Lerman, and A. Lerman
The Interaction Between Coronary Endothelial Dysfunction, Local Oxidative Stress, and Endogenous Nitric Oxide in Humans
Hypertension, January 1, 2008; 51(1): 127 - 133.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Sabatine, D. A. Morrow, M. O'Donoghue, K. A. Jablonksi, M. M. Rice, S. Solomon, Y. Rosenberg, M. J. Domanski, J. Hsia, and for the PEACE Investigators
Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease
Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2463 - 2469.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. C. White, P. Rastogi, and J. McHowat
Lysoplasmenylcholine increases neutrophil adherence to human coronary artery endothelial cells
Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1467 - C1471.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
V. G. Saougos, A. P. Tambaki, M. Kalogirou, M. Kostapanos, I. F. Gazi, R. L. Wolfert, M. Elisaf, and A. D. Tselepis
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2
Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2236 - 2243.
[Abstract] [Full Text] [PDF]